CG Oncology Inc. Common stock (CGON) Stock Forecast: StockMap's 2-Week Call
CGON stock forecast: StockMap's model makes no two-week call on CG Oncology Inc. Common stock after the Nov 19 close: its evidence is split, 6 reasons for and 9 against. Right in 4 of 4 two-week windows on CGON since Aug 21; by chance, a call on the same dates was right 69% of the time.
CG Oncology Inc. Common stock last closed at $81.90, +2.38% on the session.
Against the IVW growth benchmark the position is +4.71% over the forecast window.
CG Oncology Inc. Common stock's market cap is $7.32B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 15 (too close to call).
Where CGON sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 6 bullish and 9 bearish.
Agreement across those insights is 40%.
20 daily calls for CGON so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks CG Oncology Inc. Common stock in the 25th percentile on return on equity, where 100 is best.
CG Oncology Inc. Common stock is classified under Health Care / Biotechnology.
StockMap tracks CG Oncology Inc. Common stock as the 38th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite CG Oncology Inc. Common stock ranks 25th of 394 in the group, against a group median of -0.27.